Anti-cytokine vaccination in autoimmune diseases
Author(s) -
Laure Delavallée,
Emilie Duvallet,
Luca Semerano,
Éric Assier,
MarieChristophe Boissier
Publication year - 2010
Publication title -
swiss medical weekly
Language(s) - English
Resource type - Journals
eISSN - 1424-7860
pISSN - 1424-3997
DOI - 10.4414/smw.2010.13108
Subject(s) - medicine , immunology , rheumatoid arthritis , vaccination , disease , autoimmune disease , immunotherapy , cytokine , immune system , autoimmunity , multiple sclerosis , myasthenia gravis , antibody
The concept of therapeutic vaccination represents a novel strategy of active immunotherapy that can be applied to autoimmune disease. The principle is to design molecules which can trigger an immune response, targeting a cytokine that is pathogenic and over-expressed in a given disease. The mostly available vaccines are an application of vaccination using either the self-protein coupled to a carrier (type I A), or a modified form of the protein engineered to include neo-epitopes (type I B). These approaches have been developed in models of several autoimmune diseases, mainly in TNFα-dependent diseases such as rheumatoid arthritis and Crohn's disease, but also in systemic lupus erythematosus, multiple sclerosis and myasthenia gravis. Clinical trials are in progress in rheumatoid arthritis, Crohn's disease and diabetes. The benefit/risk ratio of anti-cytokine vaccination is currently under study to further develop the vaccination strategies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom